Retireful LLC Invests $763,000 in Eli Lilly and Company

The investment firm acquired 707 shares of the pharmaceutical giant in Q4 2025.

Apr. 4, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Retireful LLC, an investment management firm, acquired a new position in Eli Lilly and Company (NYSE:LLY) during the fourth quarter of 2025. According to the firm's most recent SEC filing, Retireful purchased 707 shares of Lilly stock valued at approximately $763,000.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor Lilly's stock performance and any significant changes in ownership, as it can signal broader market trends and investor sentiment around the company.

The details

Retireful LLC's investment in Eli Lilly and Company is part of a broader trend of institutional investors adding the stock to their portfolios. Several other hedge funds and investment firms have also recently increased or initiated positions in Lilly, including 10Elms LLP, M.E. Allison & CO. Inc., Bridgewater Advisors Inc., and Manske Wealth Management.

  • Retireful LLC acquired the 707 shares of Lilly stock in the fourth quarter of 2025.
  • The investment firm filed the details of its Lilly position with the SEC on April 4, 2026.

The players

Retireful LLC

An investment management firm that acquired a new position in Eli Lilly and Company during the fourth quarter of 2025.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

Retireful LLC's investment in Eli Lilly reflects the continued interest and confidence of institutional investors in the pharmaceutical company's long-term growth potential. Lilly's diverse product pipeline, global reach, and strong financial performance make it an attractive option for investors seeking exposure to the healthcare sector.